Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Two prominent players in the healthcare sector are Amgen and CRISPR Therapeutics, each presenting distinct opportunities for investors in 2026. Amgen, a multinational biopharmaceutical company, boasts a diverse portfolio of established drugs addressing significant health issues such as heart disease, obesity, and rare diseases. Its extensive reach extends to over 100 countries, with products distributed through major wholesalers like McKesson, Cencora, and Cardinal Health, which collectively accounted for nearly 77% of global gross revenues in 2025.

However, the concentration of revenue in these three entities introduces a degree of risk due to the potential for market fluctuations impacting the company. On the other hand, CRISPR Therapeutics stands at the forefront of groundbreaking gene-editing technology, having recently introduced its first commercial product, positioning itself as a pioneer in the rapidly evolving field of genetic therapies.

This innovative approach offers the potential for revolutionary breakthroughs in treating genetic disorders, but it comes with inherent uncertainties tied to the early stages of clinical development and regulatory approvals. When weighing the two, investors must carefully consider their risk appetite and investment horizon. Amgen's status as a well-established player with a diversified product line and strong market presence may appeal to those seeking stability and reliable dividends.

Conversely, CRISPR Therapeutics' pioneering spirit and potential for transformative breakthroughs attract those willing to embrace higher risk for the possibility of substantial long-term gains. In 2026, the choice between these two healthcare stocks will ultimately hinge on which trajectory aligns better with an investor's strategic goals—whether that be capitalizing on established market dominance or betting on the future of cutting-edge genetic therapies.